Characterization of an anticryptococcal protein isolated from human serum

Infection and Immunity

Volumn 68, Issue 6, 2000, Pages 3787-3791

  Sridhar, Sridevi ^a   Ahluwalia, Mala ^a   Brummer, Elmer ^a,b   Stevens, David A ^a,b,c  

^a CALIFORNIA INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SANTA CLARA VALLEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOTRANSFERRIN; FERRIC CHLORIDE;

AMINO ACID SEQUENCE; ARTICLE; CRYPTOCOCCUS NEOFORMANS; FUNGUS GROWTH; GROWTH INHIBITION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN ISOLATION;

ANTIFUNGAL AGENTS; APOPROTEINS; BLOOD PROTEINS; CRYPTOCOCCUS NEOFORMANS; FERRIC COMPOUNDS; HUMANS; IMMUNITY, NATURAL; TRANSFERRIN;

EID: 0034128271     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.68.6.3787-3791.2000     Document Type: Article

References (18)

1. Baum, G. L., and D. Artis. 1961. Growth inhibition of Cryptococcus neoformans by cell free human serum. J. Med Sci. 241:613-616.
2. Baum, G. L., and D. Artis. 1963. Characterization of the growth inhibition factor for Cryptococcus neoformans in human serum. Am. J. Med. 87:53-57.
3. Brummer, E. 1999. Human defenses against Cryptococcus neoformans: an update. Mycopathologia 145:121-125.
4. Collins, V. P., A. Gellhorn, and J. R. Trimble. 1951. The coincidence of cryptococcosis and disease of the reticuloendothelial system. Cancer 4:883-889.
5. Duvvuru, S., E. Brummer, R. Morelli, and D. A. Stevens. 1999. Isolation of a human serum protein that inhibits the growth of Cryptococcus neoformans. Mycopathologia 144:1-7.
6. Esterly, N. B., S. R. Brammer, and R. G. Crounse. 1967. The relationship of transferrin and iron to serum inhibition of Candida albicans. J. Investig. Dermatol. 49:437-442.
7. Gadebusch, H. H. 1965. Anticryptococcal serum factors in malignant reticuloendothelioses in man, p. 640-648. Antimicrob. Agents Chemother. 1964.
8. Gendel, B. R., M. Ende, and S. L. Norman. 1950. Cryptococcosis: a review with special reference to apparent association with Hodgkin's disease. Am. J. Med. 9:343-355.
9. Grover, D. D., E. Brummer, and D. A. Stevens. 1996. Study of the role of iron in the anticryptococcal activity of human serum and fluconazole. Mycopathologia 133:71-77.
10. Hendry, A. T., and A. Bakerspigel. 1969. Factors affecting serum inhibited growth of Candida albicans and Cryptococcus neoformans. Sabouraudia 7:219-229.
11. Howard, D. H. 1961. Some factors which affect the initiation of growth of Cryptococcus neoformans. J. Bacteriol. 82:340-345.
12. Igel, J. H., and R. P. Bolande. 1966. Humoral defense mechanisms in cryptococcosis: substances in normal human serum, saliva, and cerebrospinal fluid affecting the growth of Cryptococcus neoformans. J. Infect. Dis. 116:75-83.
13. Jacobson, E. S., A. P. Goodner, and K. J. Nyhus. 1998. Ferrous iron uptake in Cryptococcus neoformans. Infect. Immun. 66:4169-4175.
14. Nassar, F., E. Brummer, and D. A. Stevens. 1995. Different components in human serum inhibit multiplication of Cryptococcus neoformans and enhance fluconazole activity. Antimicrob. Agents Chemother. 39:2490-2493.
15. Nyhus, K. J., A. T. Wilborn, and E. S. Jacobson. 1997. Ferric iron reduction by Cryptococcus neoformans. Infect. Immun. 65:434-438.
16. Reiss, F., G. Szilagyi, and E. Mayer. 1975. Immunological studies of the anticryptococcal factor of normal human serum. Mycopathologia 55:175-178.
17. Shiraishi, A., and T. Arai. 1974. Antifungal activity of transferrin. Sabouraudia 17:79-83.
18. Szilagyi, G., F. Reiss, and J. C. Smith. 1996. The anticryptococcal factor of blood serum. J. Investig. Dermatol. 46:306-308.